You're funny. :(
You obviously know absolutely nothing about the company. Maybe you should do some research before mouthing off, like some "analysts". Or, you may just want it to fail and not provide drugs and products to help millions of people.
Long and patient since $4s. :)
Out of ALL the posts, I have only 1-4 posts per day because of all the idiots I put on ignore. Those are the ones who: constantly bash, have lame#$%$ IDs, write garbled nonsense, talk about and respond to the lame#$%$ IDs.
Sometimes there is something worth reading. Mostly I get info on OPK from uncleltzz site.
Yes, although I do worry about the PR effect and resulting big stock decline on the company, should the good Doctor not be able to bring this home for health reasons. Just need 2-3 years.
Long and patient since $4s
It is, but I expect it to go down more. Maybe we'll see $8:50 even. Trying to decide where I will buy more.
Long since $4s.
Some people have a hard time holding a stock as it goes down and need to sell. Then there's the big firms that it's status quo.
I am now seeking another point to buy more. I think this may go down more as Brexit kills most stocks (except most utilities and related companies, REITS and some one-offs from what I can see in my IRA portfolio).
Sucks but we knew this would happen if Brexit happened.
Not likely, unfortunately. Just not that kind of day.
Utilities and REITS are where it is at today. I hold a handful of those types and they are green. Everything is very red. :(
99.9% of posts here add nothing and seem like they are posted by 10 y.o. kids.with their lame#$%$ IDs and slamming each other. google 'uncleltzz opk' for a message board that is factual and has value. ;)
Excepts of interview: Ronnie Moas (top 3% of WS analysts) of Standpoint Research provided his exclusive insights on the company:
Strong Management: CEO Phillip Frost is crucial to the company’s success. The analyst states, “Opko has highly experienced management; its CEO Dr. Phillip Frost has a proven track record of building and growing two successful biopharma companies.” The analyst also praises Frost’s ability to consistently delivery returns to shareholders, which he also credits for OPKO’s valuation of over $5 billion. The CEO is known for frequent insider trading, often buying shares of his own company in transactions valued from $50,000 to over $7 million. These trades result in a profitable transaction rate of 58% with a 15.8% average return per transaction. The CEO currently owns $1.6 billion (33%) of his company.
Pipeline: Moas praises the company’s strong pipeline, commenting, “OPK has a strong pipeline of drugs and technology, having generated $291 million in revenue in q12016-over 8x versus the same quarter last year.”
the analyst predicts annual sales of $500 million from Rayaldee by 2018.
...4Kscore as a positive catalyst. The 4Kscore is Opko’s unique blood test that identifies the risk of aggressive prostate cancer, marking a $2 billion market opportunity in the U.S. The analyst states, “The 4Kscore test could become a strong revenue generator for the company in the near term,” and predicts annual sales of $200 million or more in the next 2 years. OPK and Tesaro’s breast cancer drug, Varubi, launched in 2015, has also started to generate revenue for the company, with a potential U.S. market opportunity of over $1 billion.
...Rayaldee, Varubi, the 4Kscore, and others, Moas predicts that Opko will continue to grow, with revenues reaching $1.2 billion in 2016 and $2.5 billion in 2018.
Agreed. The potential for this stock is very high. Best to hold and be patient. Patience is the tough part along with watching the price bounce around...for now. ;)
How old are you? 10?
Please people. Put these loser IDs on /ignore. There are SO many that all posts are grey. heh. Or, even better, to go to (google) uncleltzz opk for news and posts that actually mean something.
Shorts will win several battles but the Longs will win the war.